These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 21965338)

  • 21. Genomic sequencing in cancer.
    Tuna M; Amos CI
    Cancer Lett; 2013 Nov; 340(2):161-70. PubMed ID: 23178448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequencing efforts help to refine the molecular classification of breast cancer.
    Konecny GE
    Curr Opin Obstet Gynecol; 2014 Feb; 26(1):18-20. PubMed ID: 24346129
    [No Abstract]   [Full Text] [Related]  

  • 23. New Advances in Molecular Breast Cancer Pathology.
    Rakha EA; Pareja FG
    Semin Cancer Biol; 2021 Jul; 72():102-113. PubMed ID: 32259641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Precision Medicine in Breast Cancer.
    Odle TG
    Radiol Technol; 2017 Mar; 88(4):401M-421M. PubMed ID: 28298516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
    Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
    Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identifying molecular drivers of gastric cancer through next-generation sequencing.
    Liang H; Kim YH
    Cancer Lett; 2013 Nov; 340(2):241-6. PubMed ID: 23178814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantification of read species behavior within whole genome sequencing of cancer genomes for the stratification and visualization of genomic variation.
    Hibsh D; Buetow KH; Yaari G; Efroni S
    Nucleic Acids Res; 2016 May; 44(9):e81. PubMed ID: 26809676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
    Pécuchet N; Legras A; Laurent-Puig P; Blons H
    Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular Genomic Testing for Breast Cancer: Utility for Surgeons.
    Fayanju OM; Park KU; Lucci A
    Ann Surg Oncol; 2018 Feb; 25(2):512-519. PubMed ID: 29159748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in Tumor Sampling and Sequencing in Breast Cancer and their Application in Precision Diagnostics and Therapeutics.
    Lee AC; Lee HB; Yeom H; Song SW; Kim SD; Choi A; Lee S; Lee Y; Han W; Kwon S
    Adv Exp Med Biol; 2021; 1187():215-244. PubMed ID: 33983581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients.
    Liang DH; Ensor JE; Liu ZB; Patel A; Patel TA; Chang JC; Rodriguez AA
    Breast Cancer Res Treat; 2016 Jan; 155(1):139-49. PubMed ID: 26667234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genomic and transcriptional heterogeneity-based precision in personalized treatment for breast cancer.
    Antoniou P; Ziogas DE; Vlachioti A; Lykoudis EG; Mitsis M; Roukos DH
    Per Med; 2019 Sep; 16(5):361-364. PubMed ID: 31507233
    [No Abstract]   [Full Text] [Related]  

  • 33. Tumour Heterogeneity of Breast Cancer: From Morphology to Personalised Medicine.
    Aleskandarany MA; Vandenberghe ME; Marchiò C; Ellis IO; Sapino A; Rakha EA
    Pathobiology; 2018; 85(1-2):23-34. PubMed ID: 29428954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Epigenomic Revolution in Breast Cancer: From Single-Gene to Genome-Wide Next-Generation Approaches.
    Davalos V; Martinez-Cardus A; Esteller M
    Am J Pathol; 2017 Oct; 187(10):2163-2174. PubMed ID: 28734945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor Heterogeneity in Breast Cancer.
    Badve S; Gökmen-Polar Y
    Adv Anat Pathol; 2015 Sep; 22(5):294-302. PubMed ID: 26262511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast.
    Ping Z; Siegal GP; Harada S; Eltoum IE; Youssef M; Shen T; He J; Huang Y; Chen D; Li Y; Bland KI; Chang HR; Shen D
    Oncotarget; 2016 Dec; 7(49):80655-80663. PubMed ID: 27811364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer.
    Guan X; Liu B; Niu Y; Dong X; Zhu X; Li C; Li L; Yi Z; Sun X; Chen H; Lu S; Ma F
    Breast; 2020 Feb; 49():261-266. PubMed ID: 31927339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Next-generation sequencing in breast cancer: first take home messages.
    Desmedt C; Voet T; Sotiriou C; Campbell PJ
    Curr Opin Oncol; 2012 Nov; 24(6):597-604. PubMed ID: 23014189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liquid biopsy in breast cancer: A comprehensive review.
    Alimirzaie S; Bagherzadeh M; Akbari MR
    Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathologic diagnosis of breast cancer patients: evolution of the traditional clinical-pathologic paradigm toward "precision" cancer therapy.
    Turner BM; Hicks DG
    Biotech Histochem; 2017; 92(3):175-200. PubMed ID: 28318327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.